Die Misteltherapie beim Mammakarzinom und Fatigue

Zusammenfassung

Die Mistel gehört in Deutschland zu den meistverordneten komplementärmedizinischen Krebsmedikamenten. Viele Patientinnen mit Mammakarzinom erhalten im Verlauf ihrer Erkrankung eine Misteltherapie. Präklinische Forschungen, klinische Studien und Übersichtsarbeiten liegen zum Einsatz der Misteltherapie beim Mammakarzinom vor. Hautsächlich findet die Mistel Anwendung bei Tumor-assoziierter Fatigue, zur Verbesserung der Lebensqualität und zur Verminderung systemtherapeutisch bedingter Nebenwirkungen.

Abstract

Mistletoe is one of the most widely prescribed complementary cancer drugs in Germany. Many patients with breast cancer receive mistletoe therapy in the course of their illness. Preclinical research, clinical studies and reviews are available on the use of mistletoe therapy in breast cancer. Mistletoe is mainly used for tumor-associated fatigue, to improve the quality of life and to reduce side effects caused by system therapy.

Schlüsselwörter

Fatigue - Mammakarzinom - Misteltherapie - Lebensqualität - Therapiekombinationen - Sicherheit

Key words

Fatigue - breast cancer - mistletoe therapy - quality of life - therapy combinations - safety

• Literatur

• 1 Yancey J, Thomas S. Chronic fatigue syndrome: diagnosis and treatment. Am Fam Physician 2012; 86: 741-746
• 2 Berger A, Mooney K, Alvarez-Perez A. et al. National comprehensive cancer network. Cancer-Related Fatigue, Version 2.2015. J Natl Compr Canc Netw 2015; 13: 1012-1039
• 3 Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO). www.ago-online.de 2020
• 4 Anonymus. Ein neues Krebsheilmittel. Cancerodoron. Neues Wiener Journal 1924; 11. Januar 1924
• 5 Hoffmann F. Versorgung mit Krebstherapeutika im Jahr 2010. In: Glaeske G, Schicktanz C. Schriftenreihe zur Gesundheitsanalyse. Schwäbisch Gmünd: Barmer GEK; 2011
• 6 Wilkens J. Misteltherapie: Differenzierte Anwendung der Mistel nach Wirtsbäumen. Stuttgart: Sonntag; 2006
• 7 Bopp A. Die Mistel – Heilpflanze in der Krebstherapie. Zürich: Rüffer & Rub; 2006
• 8 Wilkens J. Misteltherapie. Differenzierte Anwendung der Mistel nach Wirtsbäumen. Stuttgart: Sonntag-Verlag; 2006: 156
• 9 Horneber MA, Bueschel G, Huber R, Linde K, Rostock M. Mistletoe therapy in oncology. Cochrane Database Syst Rev 2008; 2008: CD003297
• 10 Tröger W, Jezdić S, Zdrale Z. et al. Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. Breast Cancer (Auckl) 2009; 3: 35-45
• 11 Tröger W, Zdrale Z, Tisma N, Matijasevic M. Additional therapy with a mistletoe product during adjuvant chemotherapy of breast cancer patients improves quality of life: An open randomized clinical pilot trial. Evid Based Complement Alternat Med 2014; 2014: 430518
• 12 Pelzer F, Tröger W, Nat DR. Complementary treatment with mistletoe extracts during chemotherapy: Safety, neutropenia, fever, and quality of life assessed in a randomized study. J Altern Complement Med 2018; 24: 954-961
• 13 Tröger W, Zdrale Z, Stankovic N, Matijasevic M. Five-year follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with Viscum album (L.) extract to chemotherapy alone. Breast Cancer (Auckl) 2012; 6: 173-180
• 14 Tröger W, Zdrale Z, Stankovic N. Fünf-Jahres-Nachbeobachtung von Patientinnen mit Brustkrebs nach einer randomisierten Studie mit Viscum album (L.) Extrakt. Dtsch Z Onkol 2016; 48: 105-110
• 15 Eisenbraun J, Scheer R, Kroz M. et al. Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract. Phytomedicine 2011; 18: 151-157
• 16 Loewe-Mesch A, Kuehn J, Borho K. et al. Adjuvant simultaneous mistletoe chemotherapy in breast cancer – influence on immunological parameters, quality of life and tolerability. Forsch Komplementmed 2008; 15: 22-30
• 17 Bar-Sela G, Wollner M, Hammer L. et al. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. Eur J Cancer 2013; 49: 1058-1064
• 18 Bock PR, Friedel WE, Hanisch J. et al. Efficacy and safety of long-term complementary treatment with standardised European mistletoe extract (VISCUM ALBUM L.) in addition to the conventional adjuvant oncological therapy in patients with primary non-metastatic breast cancer. Arzneimittel-Forschung/Drug Research 2004; 54: 456-466
• 19 Büssing A, Raak C, Ostermann T. Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis. Evid Based Complement Alternat Med 2012; 2012: 219402
• 20 Beuth J, Schneider B, Schierholz JM. Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study. Anticancer Res 2008; 28: 523-527
• 21 Kienle GS, Glockmann A, Schink M, Kiene H. Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res 2009; 28: 79
• 22 Nazaruk J, Orlikowski P. Phytochemical profile and therapeutic potential of Viscum album L. Nat Prod Res 2016; 30: 373-385
• 23 Oei SL, Thronicke A, Schad F. Mistletoe and immunomodulation: Insights and implications for anticancer therapies. Evid Based Complement Alternat Med 2019; 2019: 5893017
• 24 Büssing A, Schietzel D, Schietzel M. et al. Keine Stimulation in vitro kultivierter Tumorzellen durch Mistellektin. Dtsch. Z Onkol 2004; 36: 66-70
• 25 Mansky PJ, Wallerstedt DB, Sannes TS. et al. NCCAM/NCI Phase 1 study of mistletoe extract and Gemcitabine in patients with advanced solid tumors. Evid Based Complement Alternat Med 2013; 2013: 964592
• 26 Weissenstein U, Kunz M, Urech K, Baumgartner S. Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro. BMC Complement Altern Med 2014; 14: 6
• 27 Hong CE, Park AK, Lyu SY. Synergistic anticancer effects of lectin and doxorubicin in breast cancer cells. Mol Cell Biochem 2014; 394: 225-235
• 28 Beuth J, Kelter G, Fischer U. et al. Tumorwachstumsstimulation durch Mistelpräparate? Fakten und Artefakte. Dtsch Z Onkol 2008; 40: 12-19
• 29 Burger AM, Mengs U, Kelter G. et al. No evidence of stimulation of human tumor cell proliferation by a standardized aqueous mistletoe extract in vitro. Anticancer Res 2003; 23: 3801-3806
• 30 Weissenstein U, Kunz M, Oufir M. et al. Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro. BMC Complement Altern Med 2019; 19: 23
• 31 Weissenstein U, Kunz M, Urech K. et al. Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro. BMC Complement Altern Med 2016; 16: 271
• 32 Greenlee H, DuPont-Reyes MJ, Balneaves LG. et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin 2017; 67: 194-232
• 33 Lyman GH, Greenlee H, Bohlke K. et al. Integrative therapies during and after breast cancer treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. J Clin Oncol 2018; 36: 2647-2655
• 34 Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO). Leitlinien/Empfehlungen: Komplementäre Therapie. Stand: 02.03.2020 www.ago-online.de/fileadmin/ago-online/downloads/_leitlinien/kommission_mamma/2020/PDF_DE/2020D%2023_Komplementaermedizin.pdf